Strategies for the Treatment of Infantile Soft Tissue Sarcomas With BCOR Alterations
- PMID: 36706311
- PMCID: PMC11225610
- DOI: 10.1097/MPH.0000000000002620
Strategies for the Treatment of Infantile Soft Tissue Sarcomas With BCOR Alterations
Abstract
BCOR alterations are described in ultra-rare infantile soft tissue sarcomas including primitive myxoid mesenchymal tumor of infancy and undifferentiated round cell sarcoma (URCS). Previous reports often describe dismal outcomes. Thus, we undertook a retrospective, multi-institutional study of infants with BCOR -rearranged soft tissue sarcomas. Nine patients aged 6 weeks to 15 months were identified. One tumor carried a BCOR :: CCNB3 fusion, whereas 7 tumors harbored internal tandem duplication of BCOR , including 4 cases classified as primitive myxoid mesenchymal tumor of infancy, 1 case as URCS, and 2 cases characterized by a "hybrid morphology" in our evaluation. Four patients underwent upfront surgery with residual disease that progressed locally after a median of 2.5 months. Locoregional recurrences were observed in hybrid patients, and the URCS case recurred with brain metastases. Complete radiographic responses after chemotherapy were achieved in patients treated with vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide, vincristine/doxorubicin/cyclophosphamide alternating with cyclophosphamide/etoposide (regimen I), and ifosfamide/carboplatin/etoposide. Seven patients received radiotherapy. With a median of 23.5 months off therapy, 8 patients are with no evidence of disease. In our study, observation was inadequate for the management of untreated postsurgical residual disease. Tumors demonstrated chemosensitivity with anthracycline-based regimens and ifosfamide/carboplatin/etoposide. Radiotherapy was required to achieve durable response in most patients.
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Similar articles
-
Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas.J Cancer Res Clin Oncol. 2023 Aug;149(9):5479-5491. doi: 10.1007/s00432-022-04454-8. Epub 2022 Dec 4. J Cancer Res Clin Oncol. 2023. PMID: 36463530 Free PMC article.
-
Recurrent BCOR Internal Tandem Duplication and YWHAE-NUTM2B Fusions in Soft Tissue Undifferentiated Round Cell Sarcoma of Infancy: Overlapping Genetic Features With Clear Cell Sarcoma of Kidney.Am J Surg Pathol. 2016 Aug;40(8):1009-20. doi: 10.1097/PAS.0000000000000629. Am J Surg Pathol. 2016. PMID: 26945340 Free PMC article.
-
A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl).Eur J Cancer. 2023 Apr;183:11-23. doi: 10.1016/j.ejca.2023.01.003. Epub 2023 Jan 18. Eur J Cancer. 2023. PMID: 36791667
-
Effectiveness of different treatment modalities for the management of adult-onset granulosa cell tumours of the ovary (primary and recurrent).Cochrane Database Syst Rev. 2014 Apr 21;2014(4):CD006912. doi: 10.1002/14651858.CD006912.pub2. Cochrane Database Syst Rev. 2014. PMID: 24753008 Free PMC article.
-
Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.Cochrane Database Syst Rev. 2017 May 25;5(5):CD007941. doi: 10.1002/14651858.CD007941.pub3. Cochrane Database Syst Rev. 2017. PMID: 28541603 Free PMC article.
References
-
- Sultan I, Casanova M, Al-Jumaily U, et al. Soft tissue sarcomas in the first year of life. Eur J Cancer. 2010;46:2449–2456. - PubMed
-
- Ferrari A, Orbach D, Sultan I, et al. Neonatal soft tissue sarcomas. Semin Fetal Neonatal Med. 2012;17:231–238. - PubMed
-
- Ferrari A, Casanova M, Bisogno G, et al. Rhabdomyosarcoma in infants younger than one year old. Cancer. 2003;97:2597–2604. - PubMed
-
- Orbach D, Sparber-Sauer M, Laetsch TW, et al. Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: international consensus and remaining controversies. Eur J Cancer. 2020;137:183–192. - PubMed
-
- Alaggio R, Ninfo V, Rosolen A, et al. Primitive myxoid mesenchymal tumor of infancy: a clinicopathologic report of 6 cases. Am J Surg Pathol. 2006;30:388–394. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical